# Kiniksa Pharmaceuticals International, plc (KNSA)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001730430

## Kiniksa Pharmaceuticals International, plc

KNSA; healthcare

| | |
|---|---|
| **Grade** | **A** ▼ A B C D E<br>strongest fifth of 371 graded peers<br>percentile 0.8; sampling error 2.5 points; lower is stronger |
| **Rank** | 4 of 371 |
| **Profitability** | B percentile 23.3 |
| **Solvency** | B percentile 33.4 |
| **Growth and financing** | A percentile 11.6 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $763.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none active<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Feb 24, 2026<br>227 days before the rescan; latest periodic filing 10-Q received Jul 28, 2026 |
| **Last close** | $78.77<br>2026-10-08; market equity $0 |
| **Price used in grade** | None |

**A, the bull**

strongest fifth of its sector; letters are fifths of the 371 graded peers

**Share price, twelve months to the rescan**

*split-adjusted close; the letter is fixed at the rescan that set it*

*Rescans on file: A from Mar 21, 2026*

## Letter at every rescan

*Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only*




## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1? ("IL-1?") and interleukin-1? ("IL-1?") cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.

## The fourteen inputs

*lower percentile is stronger; equal-weighted sleeves*

| Input | Percentile, 0 to 100 | Value | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 23.3** | | | | | | |
| Gross profitability | | 78.6% | 32.2% | 10.0 | 372 | 2025-12-31 |
| Return on invested capital | | not computable | 9.3% | | | one or more required annual facts are missing |
| Accruals ratio | | (11.8%) | (6.6%) | 36.7 | 811 | 2025-12-31 |
| Gross margin stability, five years | | not computable | 2.8 pts | | | five annual gross margins are required; found 3 |
| **Solvency, sleeve percentile 33.4** | | | | | | |
| Twelve-month failure probability | | not computable | 0.07% | | | liabilities and a nearby cover-page share count are required at 2026-03-31 |
| Altman Z double-prime | | 5.08 | (0.31) | 18.5 | 756 | 2025-12-31 |
| Net debt to EBITDA | | not computable | 1.82x | | | one or more required annual facts are missing |
| Interest coverage | | not computable | (4.51x) | | | one or more required annual facts are missing |
| Current ratio | | 3.79x | 2.96x | 48.2 | 839 | 2025-12-31 |
| **Growth and financing, sleeve percentile 11.6** | | | | | | |
| Revenue growth, three-year compound | | 45.5% | 10.0% | 14.5 | 415 | 2025-12-31 |
| Free cash flow growth, three-year compound | | 188.1% | 10.9% | 1.1 | 96 | 2025-12-31 |
| Reinvestment rate | | 308.5% | 37.1% | 8.7 | 104 | 2025-12-31 |
| Asset growth, three years | | 18.4% | 2.1% | 22.2 | 704 | 2025-12-31 |
| Net share issuance, one year | | not computable | 2.5% | | | two annual share counts are required; found 0 |

## Among 371 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 1 | Protagonist Therapeutics, Inc. (PTGX) | 0.0 | A | fortress |
| 2 | Delcath Systems, Inc. (DCTH) | 0.3 | A | balance sheet fortress |
| 3 | Inspire Medical Systems, Inc. (INSP) | 0.5 | A | balance sheet fortress |
| 4 | Kiniksa Pharmaceuticals International, plc (KNSA) < | 0.8 | A | balance sheet |
| 5 | Mimedx Group, Inc. (MDXG) | 1.1 | A | fortress |
| 6 | Harmony Biosciences Holdings, Inc. (HRMY) | 1.4 | A | balance sheet fortress |
| 7 | BeOne Medicines Ltd. (ONC) | 1.6 | A | balance sheet fortress |
| 8 | Progyny, Inc. (PGNY) | 1.9 | A | balance sheet |
| 9 | Exelixis, Inc. (EXEL) | 2.2 | A | fortress |
| | | | | balance sheet |

## What the price implies

*at the 2026-10-08 close; none enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 102.5% | 8.0% | 88 |
| Distance from 52-week high | (2.7%) | (31.4%) | 96 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.28 | |
| Sales to price | not computable | 0.31 | |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | 0.49 | (0.14) | 88 |

## Diagnostics

*not in the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $190.0M |
| Operating cash flow, four quarters | $165.9M |
| Months of runway | not finite |
| Days since last periodic filing | 73 (10-Q received Jul 28, 2026) |
| Median daily dollar volume, 63 sessions | $34.4M |

## Sources

*each row links to the filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $677.6M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $77.7M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 3 | assets | us-gaap:Assets | $763.6M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 4 | net income | us-gaap:NetIncomeLoss | $59.0M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $138.0M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 6 | assets | us-gaap:Assets | $580.6M | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 7 | current assets | us-gaap:AssetsCurrent | $527.2M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $139.2M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$462.1M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | $77.2M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 11 | book equity | us-gaap:StockholdersEquity | $567.6M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 12 | liabilities | us-gaap:Liabilities | $196.0M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $423.2M | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $270.3M | 2023-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $220.2M | 2022-12-31 | 2025-02-25 | 10-K | 0001558370-25-001505 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.6M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $25.7M | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $277,000 | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $13.3M | 2023-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $130,000 | 2023-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $5.8M | 2022-12-31 | 2025-02-25 | 10-K | 0001558370-25-001505 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $105,000 | 2022-12-31 | 2025-02-25 | 10-K | 0001558370-25-001505 |
| 23 | depreciation amortization | us-gaap:Depreciation | $196,000 | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 24 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $88.9M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 25 | income tax | us-gaap:IncomeTaxExpenseBenefit | $29.9M | 2025-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 26 | current assets | us-gaap:AssetsCurrent | $331.8M | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $100.6M | 2024-12-31 | 2026-02-24 | 10-K | 0001104659-26-019168 |
| 28 | assets | us-gaap:Assets | $526.3M | 2023-12-31 | 2025-02-25 | 10-K | 0001558370-25-001505 |
| 29 | assets | us-gaap:Assets | $459.7M | 2022-12-31 | 2024-02-28 | 10-K | 0001558370-24-002005 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.